Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Abstract Background The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB). In this analysis of PREFER, patient-reported outco...

Full description

Bibliographic Details
Main Authors: Sender Herschorn, David Staskin, Le Mai Tu, Jonathan Fialkov, Terry Walsh, Katherine Gooch, Carol R. Schermer
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Health and Quality of Life Outcomes
Subjects:
Mirabegron
Tolterodine ER
Overactive bladder
OAB-questionnaire
Health-related quality of life
OAB-satisfaction
Online Access:http://link.springer.com/article/10.1186/s12955-018-0892-0

Internet

http://link.springer.com/article/10.1186/s12955-018-0892-0

Similar Items